HARP: מזומנים בחישוב למניה אחת Harpoon Therapeutics Corp

Harpoon Therapeutics (HARP) develops unique TriTAC antibodies that link tumors and T-cells to combat cancer. Revenues are based on the supply of carcinoma therapy drugs to oncology clinics. Cash per share demonstrates financial stability, with the value of 1.47 serving as the current metric. Growth prospects depend on the long-term results of late-stage clinical trials.
פילוחי מדדים מקיפים ואנליטיקה עבור harpoontx.com (HARP)

Harpoon Therapeutics focuses on developing anticancer immunotherapies without current operating revenue. The 1.47 metric reflects the share of liquid assets per common share. This metric allows for an assessment of the company's financial cushion to continue costly clinical trials. It is critical for investors to monitor the burn rate until the drugs reach commercialization. The price action of cash per share clearly demonstrates the current pace of cash burn.